Novo Nordisk A/S banner

Novo Nordisk A/S
F:NOV

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
F:NOV
Watchlist
Price: 42.3 EUR 0.74% Market Closed
Market Cap: €142.8B

Wall St Price Targets

NOV Price Targets Summary
Novo Nordisk A/S

Wall Street analysts forecast NOV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NOV is 43.3 EUR with a low forecast of 26.69 EUR and a high forecast of 62.98 EUR.

Lowest Forecast
Price Target
26.69 EUR
37% Downside
Average Forecast
Price Target
43.3 EUR
2% Upside
Highest Forecast
Price Target
62.98 EUR
49% Upside
Novo Nordisk A/S Competitors:
Price Targets

Revenue
Forecast

12% / Year
Past Growth
1% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
12% / Year
Past Growth
1% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 3 years is 1%.

Gross Profit
Forecast

12% / Year
Past Growth
2% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
12% / Year
Past Growth
2% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 2%.

Operating Income
Forecast

13% / Year
Past Growth
2% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
13% / Year
Past Growth
2% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 14 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 3 years is 2%.

Pre-Tax Income
Forecast

14% / Year
Past Growth
0% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
14% / Year
Past Growth
0% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 14%. The projected CAGR for the next 3 years is 0%.

Net Income
Forecast

14% / Year
Past Growth
-1% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
14% / Year
Past Growth
-1% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 14 years, the compound annual growth rate for Net Income has been 14%. The projected CAGR for the next 3 years is -1%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is NOV's stock price target?
Price Target
43.3 EUR

According to Wall Street analysts, the average 1-year price target for NOV is 43.3 EUR with a low forecast of 26.69 EUR and a high forecast of 62.98 EUR.

What is the Revenue forecast for Novo Nordisk A/S?
Projected CAGR
1%

Over the last 14 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 3 years is 1%.

What is the Gross Profit forecast for Novo Nordisk A/S?
Projected CAGR
2%

Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 2%.

What is the Operating Income forecast for Novo Nordisk A/S?
Projected CAGR
2%

Over the last 14 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 3 years is 2%.

What is the Pre-Tax Income forecast for Novo Nordisk A/S?
Projected CAGR
0%

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 14%. The projected CAGR for the next 3 years is 0%.

What is the Net Income forecast for Novo Nordisk A/S?
Projected CAGR
-1%

Over the last 14 years, the compound annual growth rate for Net Income has been 14%. The projected CAGR for the next 3 years is -1%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett